Matches in Wikidata for { <http://www.wikidata.org/entity/Q90808572> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q90808572 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90808572 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90808572 description "scientific article published on 29 March 2020" @default.
- Q90808572 description "wetenschappelijk artikel" @default.
- Q90808572 description "наукова стаття, опублікована 29 березня 2020" @default.
- Q90808572 name "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 name "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 type Item @default.
- Q90808572 label "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 label "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 prefLabel "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 prefLabel "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 P1433 Q90808572-2D1A2D58-71EB-4D0F-83B4-BEF181021ED4 @default.
- Q90808572 P1476 Q90808572-0A973687-8FFC-42AF-B45A-A39F0027830F @default.
- Q90808572 P2093 Q90808572-3E94C6FA-81B4-42DF-B8C5-817B214ECE59 @default.
- Q90808572 P2093 Q90808572-3F847373-79FE-4482-B549-6844FFFC45DF @default.
- Q90808572 P2093 Q90808572-4F1E4345-147C-4E1A-9EF6-162E3FFF14E5 @default.
- Q90808572 P2093 Q90808572-535115AA-0F91-43CC-9F91-E4490430561C @default.
- Q90808572 P2093 Q90808572-744B3AAA-18C1-4A73-B9E9-1C5A5A8D7AA9 @default.
- Q90808572 P2093 Q90808572-838E7852-594F-4761-9E0B-45C8700A0432 @default.
- Q90808572 P2093 Q90808572-91F31870-07E3-4A17-8302-AEFB8A145B9A @default.
- Q90808572 P2093 Q90808572-A1220D80-39FC-4EE3-BBBC-5E40DC71981A @default.
- Q90808572 P2093 Q90808572-AE44486F-9A9B-43BE-9D24-DD290571EA7E @default.
- Q90808572 P2093 Q90808572-B06B57A4-E668-44B6-B097-532A708B0C46 @default.
- Q90808572 P2093 Q90808572-BA5310B0-9674-4D7C-B92F-503BCB997831 @default.
- Q90808572 P2093 Q90808572-C0A1B0DF-ECB9-4D34-8773-89F7AB964076 @default.
- Q90808572 P2093 Q90808572-DA5F72C3-432F-449B-8AF3-9D0871AA2649 @default.
- Q90808572 P2093 Q90808572-E2F05133-BA33-4FB8-A2AA-00FA443378FB @default.
- Q90808572 P2093 Q90808572-F3536578-1014-4853-9ADF-8F9998F37F84 @default.
- Q90808572 P2093 Q90808572-FAAFC25D-2A70-430D-9133-E5F3C3FAF70B @default.
- Q90808572 P275 Q90808572-8b286e8b-1f8b-4205-9ca2-895712333f94 @default.
- Q90808572 P2860 Q90808572-7579699F-65EF-49DE-9490-6C42DC564799 @default.
- Q90808572 P31 Q90808572-781FAE19-C968-4E38-99B8-40E364235ED6 @default.
- Q90808572 P356 Q90808572-5BC4C289-4B6F-4B1B-9376-8E94E91D91BB @default.
- Q90808572 P433 Q90808572-6707F580-77F8-4E66-9C36-16759594ECE1 @default.
- Q90808572 P478 Q90808572-55806260-83F9-417E-AF34-20203DA3FD4B @default.
- Q90808572 P577 Q90808572-F44AB279-5668-416E-9AFF-9B77951AFFBA @default.
- Q90808572 P6216 Q90808572-9782e23c-6b8b-408c-ae98-4dcae5f13a2e @default.
- Q90808572 P698 Q90808572-28AD386B-58D5-4621-BA3F-852151949231 @default.
- Q90808572 P921 Q90808572-455C22EB-051B-4389-BE97-012181FE373F @default.
- Q90808572 P932 Q90808572-F9D24FB6-54E8-45FC-98F8-1DB29862C735 @default.
- Q90808572 P356 ANTIBIOTICS9040145 @default.
- Q90808572 P698 32235367 @default.
- Q90808572 P1433 Q27725829 @default.
- Q90808572 P1476 "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" @default.
- Q90808572 P2093 "Akira Mitoro" @default.
- Q90808572 P2093 "Daisuke Kaya" @default.
- Q90808572 P2093 "Hideto Kawaratani" @default.
- Q90808572 P2093 "Hiroaki Takaya" @default.
- Q90808572 P2093 "Hitoshi Yoshiji" @default.
- Q90808572 P2093 "Kei Moriya" @default.
- Q90808572 P2093 "Koh Kitagawa" @default.
- Q90808572 P2093 "Kosuke Kaji" @default.
- Q90808572 P2093 "Masanori Furukawa" @default.
- Q90808572 P2093 "Soichiro Saikawa" @default.
- Q90808572 P2093 "Tadashi Namisaki" @default.
- Q90808572 P2093 "Takahiro Ozutsumi" @default.
- Q90808572 P2093 "Takemi Akahane" @default.
- Q90808572 P2093 "Yasuhiko Sawada" @default.
- Q90808572 P2093 "Yuki Tsuji" @default.
- Q90808572 P2093 "Yukihisa Fujinaga" @default.
- Q90808572 P275 Q20007257 @default.
- Q90808572 P2860 Q24647611 @default.
- Q90808572 P31 Q13442814 @default.
- Q90808572 P356 "10.3390/ANTIBIOTICS9040145" @default.
- Q90808572 P433 "4" @default.
- Q90808572 P478 "9" @default.
- Q90808572 P577 "2020-03-29T00:00:00Z" @default.
- Q90808572 P6216 Q50423863 @default.
- Q90808572 P698 "32235367" @default.
- Q90808572 P921 Q5832599 @default.
- Q90808572 P932 "7235723" @default.